Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses whether he would recommend FDA-approved PARP inhibitors (ie, olaparib, rucaparib) in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in homologous recombination repair (HRR) genes other than BRCA1/2. In the pivotal PROFOUND trial of olaparib in mCRPC, researchers examined PARP inhibition in patients with at least 1 of 15 different genes with a direct or indirect role in HRR: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. In the video, Abida explains how the specific mutation type determines whether or not he feels comfortable recommending a PARP inhibitor for a patient.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.